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Background and Purpose Data on safety and efficacy of intra-arterial (IA) fibrinolytics as adjunct 
to mechanical thrombectomy (MT) are sparse. 
Methods INtra-arterial FIbriNolytics In ThrombectomY (INFINITY) is a retrospective multi-center 
observational registry of consecutive patients with anterior circulation large-vessel occlusion isch-
emic stroke treated with MT and adjunctive administration of IA fibrinolytics (alteplase [tissue plas-
minogen activator, tPA] or urokinase [UK]) at 10 European centers. Primary outcome was the oc-
currence of symptomatic intracranial hemorrhage (sICH) according to the European Cooperative 
Acute Stroke Study II definition. Secondary outcomes were mortality and modified Rankin Scale 
(mRS) scores at 3 months. 
Results Of 5,612 patients screened, 311 (median age, 74 years; 44.1% female) received additional 
IA after or during MT (194 MT+IA tPA, 117 MT+IA UK). IA fibrinolytics were mostly administered for 
rescue of thrombolysis in cerebral infarction (TICI) 0-2b after MT (80.4%, 250/311). sICH occurred 
in 27 of 308 patients (8.8%), with an increased risk in patients with initial TICI0/1 (adjusted odds 
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Introduction
Despite recent advances in technical efficacy, incomplete and 
failed reperfusion results remain a significant concern and re-
duce the clinical benefit of mechanical thrombectomy (MT).1-5 
Although the rates of thrombolysis in cerebral infarction (TICI) 3 
reperfusions are constantly improving, in more than half of pa-
tients treated with MT, reperfusion is incomplete or no reperfu-
sion is established.4-6 Potential rescue strategies consist of intra-
cranial-stenting,7-9 mechanical removal of small distal clots10-12 
and administration of antiplatelets13 or fibrinolytics.14-16
The updated 2019 American Heart Association/American 
Stroke Association guidelines state that the use of salvage 
technical adjuncts, including intra-arterial (IA) thrombolysis, 
may be reasonable to achieve mTICI grade 2b/3 angiographic 
results.17 According to a recent survey, 39% of the responders 
stated to use IA recombinant tissue plasminogen activator 
(tPA) on individual case basis during MT.18 Observational data 
suggested the use of IA fibrinolytics during MT as a therapy 
option in selected patients, potentially improving reperfu-
sion.14-16,19 However, there were mixed signals regarding a po-
tential increase in symptomatic intracranial hemorrhage (sICH) 
and evidence regarding its treatment effect leading to im-
proved reperfusion is still limited.14-16
Aim of this multi-center analysis was to report on frequency, 
indication, safety and efficacy of IA fibrinolytics as adjunct to 
mechanical thrombectomy in consecutive patients from ten Eu-
ropean tertiary care centers.
Methods
Patients
Ten European tertiary care centers with local prospective 
thrombectomy databases were invited to participate in this 
retrospective pooled individual patient data analysis (registry 
name: INtra-arterial FIbriNolytics In ThrombectomY [INFINITY]). 
All consecutive patients treated with MT and IA administration 
of alteplase (referred to as tPA) or urokinase (referred to as UK) 
were included. Participating centers were asked to contribute 
all patients in whom IA fibrinolytics were administered during 
or after MT for an intracranial internal carotid artery (ICA), M1 
or M2 occlusion. Centers were invited to report rates of MT for 
these occlusion sites without additional IA fibrinolytics (Table 
1). Data for all patients were collected using a standardized 
form with predefined variables. Local investigators completed 
the forms systematically using data from prospectively ascer-
tained in-hospital thrombolysis or stroke registries enhanced 
with additional data from patients’ records and charts. Com-
pleted forms from all centers were sent to the coordinating 
center in Bern, where analyses of pooled data were performed.
All patients were treated with approved second-generation 
devices, i.e., stent-retriever or large-bore aspiration catheters 
or a combination thereof. Ethical approval was obtained from 
all local ethics committees. Consent was waived according to 
the retrospective nature of the work, or patients gave their 
written or oral consent, depending on the centers ethical and 
institutional guidelines. Baseline characteristics and patient 
demographics were extracted from the centers prospective 
stroke databases. Functional outcome was assessed at three 
months using the modified Rankin Scale (mRS). The score was 
evaluated by a neurologist during an outpatient visit or during 
a structured telephone interview by a mRS-certified nurse. 
Functional independence was defined as mRS ≤2. Day 90 func-
tional outcome was available for 300/311 patients (96.5%).
Image analysis
In each participating site, all images of the center’s patients 
treated with MT and adjunctive administration of IA fibrinolyt-
ics were reevaluated by a neurointerventionalist. Indication for 
administering IA fibrinolytics was determined by reviewing an-
ratio [aOR], 2.3; 95% confidence interval [CI], 1.1 to 5.0 per TICI grade decrease) or in those with 
intracranial internal carotid artery occlusions (aOR, 3.7; 95% CI, 1.2 to 12.5). In patients with at-
tempted rescue of TICI0-2b and available angiographic follow-up, 116 of 228 patients (50.9%) 
showed any angiographic reperfusion improvement after IA fibrinolytics, which was associated 
with mRS ≤2 (aOR, 3.1; 95% CI, 1.4 to 6.9).
Conclusions Administration of IA fibrinolytics as adjunct to MT is performed rarely, but can improve 
reperfusion, which is associated with better outcomes. Despite a selection bias, an increased risk of 
sICH seems possible, which underlines the importance of careful patient selection.
Keywords Tissue plasminogen activator; Stroke; Thrombolytic therapy; Thrombectomy; Intracranial 
hemorrhages
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giographic images and the angiographic report. For this pur-
pose, indications were classified into (1) rescue of TICI0-2b re-
perfusions after MT; (2) treatment of emboli in a new territory; 
or (3) administration before or during the first or second stent-
retriever deployment at the operator’s discretion. In cases of 
rescue for TICI0-2b reperfusions, images were assessed before 
and after administration of IA fibrinolytics. For this purpose, 
TICI grades before and after administration of IA fibrinolytics 
were documented. Moreover the occurrence of any angio-
graphic reperfusion improvement, defined as a reduction of 
capillary phase deficit by newly established antegrade flow, 
was assessed. By definition, any angiographic reperfusion im-
provement could therefore include cases with and without a 
TICI grade change. This angiographic data was available in 
228/250 patients with attempted rescue of TICI0-2b, because 
in 22 patients no angiography runs after administration of IA 
fibrinolytics were performed. sICH was defined as any intracra-
nial hemorrhage on follow-up imaging and clinical deteriora-
tion, as evidenced by an increase in the National Institutes of 
Health Stroke Scale (NIHSS) score of ≥4 without a mandatory 
confirmed causal relationship between clinical worsening and 
occurrence of ICH.20 
Statistical analysis
Data are presented as median (interquartile range [IQR]) or as 
number (%). Frequency comparisons were performed using Fish-
er’s exact test. Non-normally distributed continuous or ordinally 
scaled variables were compared using Whitney-Mann U test. For 
calculation of 95% confidence intervals (CIs) of frequency 
counts, we used the methods outlined by Clopper and Pearson,21 
known as the exact binomial CI. To evaluate an association be-
tween two variables over multiple strata we calculated a Man-
tel-Haenszel common odds ratio (OR) and assessed heterogene-
ity of ORs using a Breslow-Day test. Clinical regression models 
were generally adjusted for age, sex, admission NIHSS, Alberta 
Stroke Program Early CT Score (ASPECTS), occlusion site, symp-
tom-onset to reperfusion intervals, and TICI scores (before ad-
ministration of IA fibrinolytics), according to clinical importance. 
For a comparison regarding IA UK versus IA tPA patients, we ad-
ditionally included variables displaying significant distribution 
imbalances between the groups. For functional outcome, we 
used a binary logistic regression analysis with functional inde-
pendence (mRS ≤2) as dependent variable. For an estimate re-
garding sICH, a binary logistic regression model was used includ-
ing the same covariates. Results are displayed as adjusted OR 
and corresponding 95% CI. Patients with missing follow-up were 
excluded from the analysis regarding functional outcome or 
mortality. No imputation methods were performed. A sensitivity 
analysis of the main outcomes was performed excluding all pa-
tients treated before 2015. Statistical analyses were carried out 
in SPSS Statistics version 25 (IBM Co., Armonk, NY, USA) and 
STATA version 15.1 (StataCorp., College Station, TX, USA).
Results
Of 5,612 patients screened, 311 (median age, 74 years; 44.1% 
female) received additional IA after or during MT (relative fre-
quency 5.5%; range across centers 0.7% to 28.1%) (Table 1). 
Patients presented with severe symptoms (median NIHSS 14; 
IQR, 9 to 19) and 170 patients (54.7%) were treated for an 
acute occlusion of the M1. Most commonly, IA fibrinolytics 
were administered via a microcatheter, which was positioned as 
distal as possible and usually just proximal to the residual oc-
clusion site (Table 1). In 250 patients (80.4%), IA fibrinolytics 
were administered for rescue of a TICI0/1 in 32 patients 
(12.8%), for rescue of TICI2a in 54 patients (21.6%) or rescue of 
TICI2b in 164 patients (65.6%) reperfusions after MT. Other in-
dications were treatment for emboli in a new territory in 12 pa-
tients (3.9%) or during first maneuvers of mechanical throm-
bectomy at the operator’s discretion in 49 patients (15.8%). In 
117 patients (37.6%, from one center), IA UK was administered, 
while 194 patients (62.4%, from nine centers) were treated 
with IA tPA. Median dose of IA tPA was 10 mg (IQR, 5 to 10) 
and median dose of IA UK was 250.000 U (IQR, 250.000 to 
500.000). IA tPA dose tended to be higher in patients with prior 
IV tPA administration (median 10 mg vs. 7.5 mg, P=0.07). For IA 
UK, dose regimens were higher in patients treated without prior 
IV tPA (median 350.000 U vs. 250.000 U, P=0.04). Of 299 pa-
tients with available data, median symptom-onset to adminis-
tration of IA thrombolytics was 256 minutes (IQR, 206 to 320). 
Correspondingly, 127 patients (42.5%) and 43 patients (14.4%) 
of patients received IA fibrinolytics beyond 4.5 and 6 hours, re-
spectively. IA fibrinolytics were administered at a median delay 
of 55 minutes (IQR, 38 to 88) after groin puncture. Other base-
line characteristics of the cohort and stratification by IA tPA 
versus IA UK can be found in Table 2. 
Safety evaluation
Of 308 patients with available imaging follow-up, 27 had sICH 
(8.8%; 95% CI, 5.9 to 12.5). Rates were numerically higher in 
patients treated with IA tPA as compared to patients treated 
with IA UK (10.3% vs. 6.1%, P=0.30). There were three missing 
imaging follow-ups in the UK group. Assuming a worst case-
scenario, the number of patients with sICH would have 
changed to 30 (9.6%; 95% CI, 6.6% to 13.5%). After adjust-
ment for clinical confounders outlined in the methods section 
Vol. 23 / No. 1 / January 2021
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Table 2. Baseline characteristics
Characteristic All patients (n=311) IA tPA (n=194) IA UK (n=117) P 
Age (yr) 74 (62.7–81.0) 75.0 (65.0–82.0) 70.8 (58.6–78.4) 0.019
Female sex 137 (44.1) 91 (46.9) 46 (39.3) 0.197
Pre-stroke independence* 283 (91.3) 0.219
Risk factors
Atrial fibrillation†  144 (47.2)  97 (50.0)  47 (32.6) 0.233
Arterial hypertension  230 (74.0)  144 (74.2)  86 (73.5) 0.895
Diabetes‡  73 (23.6)  57 (29.4)  16 (13.9) 0.002§
Coronary artery diseasell  110 (36.4)  85 (45.9)  25 (21.4) <0.001§
Smoking  92 (29.6)  63 (32.5)  29 (31.5) 0.160
Antiplatelets¶ 0.088
None  220 (71.4)  146 (75.6)   74 (64.3)
Aspirin  79 (25.6)  43 (22.3)  36 (31.3)
Aspirin+clopidogrel/prasugrel  9 (2.9)  4 (2.1)  5 (4.3)
Oral anticoagulation‡ 0.049**
None  259 (83.8)  155 (80.3)  104 (89.7)
Vitamin K antagonists  25 (8.1)  17 (8.8)  8 (6.9)
Direct oral anticoagulants  25 (8.1)  21(10.9)  4 (3.5)
Witnessed symptom-onset 258 (83.0) 168 (86.6) 90 (76.9)
Symptom-onset/last-seen well to admission (min)†† 80 (56–150) 75 (50–137) 83 (65–160) 0.027**
Admission National Institute of Health Stroke Scale 14 (9–19) 15 (10–18) 13 (8–19) 0.374
Admission Imaging <0.001§
CT  186 (59.8)  148 (76.3)  38 (32.5)
MRI  125 (40.2)  46 (23.7)  79 (67.5)
Alberta Stroke Program Early CT Score (ASPECTS)‡ 9 (7–10) 9 (8–10) 7 (6–9) <0.001§
ASPECTS based on non-contrast CT 9 (8–10) 10 (9–10) 8 (6–9) <0.001§
ASPECTS based on MRI (diffusion-weighted imaging) 7 (6–9) 8 (7–9) 7 (5–8) 0.098
Occlusion site 0.648
Intracranial ICA  64 (20.6) 38 (19.6) 26 (22.2) 
First segment of the middle cerebral artery  170 (54.7) 110 (56.7) 60 (51.3)
Second segment of the middle cerebral artery  77 (24.8) 46 (23.7) 31 (26.5)
Intravenous tissue plasminogen activator 156 (50.2) 107 (55.2) 49 (41.9) 0.026**
Indication for IA fibrinolytics <0.001§
Rescue thromoblysis in cerebral infarction 0-2b 
  reperfusion
 250 (80.4)  168 (86.6)  82 (70.1)
Treatment of emboli to new territory  12 (3.9)  4 (2.1)  8 (6.8)
Other/individual operator decision  49 (15.8)  22 (11.3)  27 (23.1)
Symptom-onset/last-seen well to IA fibrinolytics (min)‡‡ 256 (206–320) 240 (189–318) 275 (230–324) 0.012**
Groin puncture to IA fibrinolytics (min)‡ 55 (38–88) 48 (30–75) 69 (48–102) <0.001§
Symptom-onset/last-seen well to reperfusion/
symptom-onset/last-seen well to final angiography 
run (min)§§
268 (213–350) 248 (200–315) 206 (250–381) <0.001§
Final TICI score 0.028**
0  9 (2.9)  2 (1.0)  7 (6.0)
1  15 (4.8)  7 (3.6)  8 (6.8)
2a  47 (15.1)  26 (13.4)  21 (17.9)
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and imbalances in baseline variables between the fibrinolytics 
groups, the point estimate favored IA UK with a trend for fewer 
sICH (adjusted odds ratio [aOR], 0.53; 95% CI, 0.27 to 1.04) 
(Supplementary Table 1 for other regression coefficients). In 
the model, there was also an association of female sex (aOR, 
0.30; 95% CI, 0.095 to 0.97) and M1/M2 occlusions ([aOR, 
0.27; 95% CI, 0.08 to 0.86] and [aOR, 0.29; 95% CI, 0.07 to 
1.14], respectively) with lower rates of sICH. Moreover, TICI 
grades before administration of IA fibrinolytics were associated 
with sICH, with a lower risk observed in better TICI grades 
(aOR, 0.43; 95% CI, 0.20 to 0.94 for TICI grade increase) (Figure 
1). The estimates also pointed towards an increased risk of 
sICH in patients with pretreatment with IV tPA (aOR, 2.33; 
95% CI, 0.75 to 7.17), prior use of Aspirin (aOR, 2.30; 95% CI, 
0.74 to 7.09, comparator no antiplatelet medication) and those 
taking direct oral anticoagulants (aOR, 3.08; 95% CI, 0.55 to 
17.28, comparator no oral anticoagulant medication); however, 
these associations did not reach statistical significance. Raw 
group comparisons of sICH occurrence with strata of antiplate-
lets and intake of oral anticoagulants can be found in Supple-
mentary Table 2. Doses of IA tPA/UK did not differ between pa-
tients with and without sICH (median 10 mg vs. 10 mg, P=0.96; 
and 250,000 IU vs. 250,000 IU, P=0.48). 
After 3 months, 50 of 300 patients (16.7%) with available 
follow-up died, with a doubled mortality rate in patients with 
sICH (eight of 26 sICH patients with available follow-up, 
30.8%). 
Angiographic efficacy
Angiographic control runs after administration of IA fibrinolyt-
ics were available, for 228 of 250 patients (91.2%), who re-
ceived IA fibrinolytics for attempted rescue of TICI0-2b reper-
fusions after MT. In 116 of those 228 (50.9%), any angiographic 
reperfusion improvement was noted, which resulted in a TICI 
grade improvement in 66 of 228 patients (28.9%) (Figure 2). 
Occurrence of any angiographic reperfusion improvement did 
not differ according to TICI strata before administration of IA 
fibrinolytics or occlusion sites (Supplementary Table 3). In 11 
patients, in whom IA fibrinolytics were administered for treat-
ment of an embolus in a new territory, successful reperfusion 
was reported in six patients (54.5%). In 49 patients, in whom 
IA fibrinolytics were administered before or during the first 
thrombectomy maneuvers at the operator’s discretion, final 
TICI grades were TICI3 in 16 patients (32.7%), TICI2b in 17 pa-
tients (34.7%), TICI2a in 13 patients (26.5%), and TICI0/1 in 
three patients (6.1%).
Functional outcome 










Figure 1. Risk of symptomatic intracranial hemorrhage (sICH) according to 
thrombolysis in cerebral infarction (TICI). Data on sICH was available in 
308/311 patients. SICH occurred in 5/33 patients (15.2%) with TICI0/1, in 
8/66 patients (12.1%) with TICI2a, in 14/187 patients (7.5%) with TICI2b 
and did not occur in 22 patients with TICI3. There was a decreased risk of 
sICH with higher TICI grade (adjusted odds ratio [aOR] per grade increase 
derived from logistic regression analysis: aOR, 0.43; 95% confidence inter-
val, 0.20 to 0.94). TICI scores used were before administration of intra-ar-
terial fibrinolytics in cases of rescue of TICI0-2b reperfusions. In other cases 
(treatment of emboli in new territory or administration during first retriev-
als at the operator’s discretion) final TICI scores were used. 
Characteristic All patients (n=311) IA tPA (n=194) IA UK (n=117) P 
2b  185 (59.5)  125 (64.4)  60 (51.3)
3  55 (17.7)  34 (17.5)  21 (17.9)
Values are presented as median (interquartile range) or number (%).
IA, intra-arterial; tPA, tissue plasminogen activator; UK, urokinase; CT, computed tomography; MRI, magnetic resonance imaging; ICA, internal carotid artery; 
TICI, thrombolysis in cerebral infarction.
* Data available for 310; †Data available for 305; ‡Data available for 309; §P<0.01; llData available for 302; ¶Data available for 308; **P<0.05; ††Data available 
for 303; ‡‡Data available for 299; §§Data available for 295.
Table 2. Continued
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mRS ≤2 (Figure 3A). Functional outcomes were better in pa-
tients receiving IA UK (OR for mRS ≤2, 2.22; 95% CI, 1.37 to 
3.60) (Figure 3B and C). However, this association was not sta-
tistically significant after adjustment for clinical confounders 
and baseline group imbalances (IA UK vs. IA tPA: adjusted OR, 
1.35; 95% CI, 0.87 to 2.09). Significant variables associated 










































Figure 2. Thrombolysis in cerebral infarction (TICI) grade change after intra-arterial (IA) fibrinolytics. (A) After IA fibrinolytics, TICI shifted towards better 
scores (TICI grade improvement noted in 28.9% of patients). (B) Most patients with TICI2b did not improve to TICI3; however, any angiographic reperfusion 
improvement was relatively common in patients with initial TICI2b reperfusions (46.1%, 70/152).
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Figure 3. Three-month functional outcome of patients treated with mechanical thrombectomy (MT) and intra-arterial (IA) fibrinolytics. (A) Three-month 
functional outcome was available for 300/311 patients treated with MT+IA fibrinolytics. Functional independence (modified Rankin Scale [mRS] ≤2) was ob-
served in 37.0% (111/300) of patients and 16.7% (50/300) of patients had died. (B, C) Functional outcomes were better in patients receiving IA urokinase (UK) 
(odds ratio for mRS ≤2, 2.22; 95% confidence interval [CI], 1.37 to 3.60). However, this association was not statistical significant after adjustment for clinical 
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with mRS ≤2 in the model were: age, admission NIHSS, TICI 
before administration of IA fibrinolytics, diabetes, coronary ar-
tery disease, and M2 occlusions (Supplementary Table 4 for 
point estimates and 95% CIs).
In patients with rescue of TICI0-2b reperfusions after MT and 
available angiographic follow-up (228 patients), any angio-
Table 3. Clinical benefit of angiographic reperfusion with strata of TICI grade before administration of IA fibrinolysis




0 ARI– 8 (100) 0 (0)
ARI+ 6 (66.7) 3 (33.3)
Total (TICI0) 14 (82.4) 3 (17.6) 1.50 (0.95-2.38)
1 ARI– 3 (75) 1 (25)
ARI+ 4 (66.7) 2 (33.3)
Total (TICI1) 7 (70) 3 (30) 1.50 (0.09–25.39)
2a ARI– 14 (77.8) 4 (22.2)
ARI+ 17 (63.0) 10 (37.0)
Total (TICI2a) 31 (68.9) 14 (31.1) 2.06 (0.53–8.00)
2b ARI– 52 (64.2) 29 (35.8)
ARI+ 36 (52.9) 32 (47.1)
Total (TICI2b) 88 (59.1) 61 (40.9) 1.59 (0.83–3.08)
All TICI ARI– 77 (69.4) 34 (30.6)
ARI+ 63 (57.3) 47 (42.7)
Total (all TICI) 140 (63.3) 81 (36.7) cOR 1.83 (1.04–3.22)*
Values are presented as number (%). Calculated using Mantel-Haenszel statistics. P for heterogeneity of OR, 0.54 (Breslow-Day test). 95% Confidence intervals of OR 
were calculated using Woolf's approximation.
TICI, thrombolysis in cerebral infarction; IA, intra-arterial; mRS modified Rankin Scale; OR, odds ratio; ARI–/+, angiographic reperfusion improvement; cOR, common 
odds ratio.
*P<0.05.
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Figure 4. Three-month functional outcome with strata of angiographic reperfusion improvement after administering intra-arterial (IA) fibrinolytics. For 
228/250 patients with an intention to improve TICI 0-2b, angiographic control runs after administration of IA fibrinolytics were available. Three-month func-
tional outcome was available in 221 of these 228 patients. (A) Any angiographic improvement was observed in 110/221 and was associated with modified 
Rankin Scale (mRS) ≤2 after adjusting for covariates outlined in the methods section (adjusted odds ratio, 3.11; 95% confidence interval, 1.41 to 6.86). (B) The 
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graphic reperfusion improvement was associated with mRS ≤2 
(aOR, 3.11; 95% CI, 1.41 to 6.86) (Figure 4) after adjusting for 
covariates outlined in the methods section. This association of 
functional independence and angiographic reperfusion im-
provement was relatively stable across strata of reperfusion 
grade achieved before administering IA fibrinolytics (common 
OR, 1.83; 95% CI, 1.04 to 3.22, P for heterogeneity of ORs, 
0.54) (Table 3). 
Sensitivity analysis
Excluding patients treated before 2015 lead to a subcohort of 
240 patients (51 patients treated with IA UK and 189 treated 
with IA tPA). In this subcohort, 23 of 239 with available data 
had sICH (9.6%). Of 240 patients, angiographic control runs 
after administration of IA fibrinolytics were available for 181 of 
203 patients (89.2%), who received IA fibrinolytics for at-
tempted rescue of TICI0-2b reperfusions after MT. In these 181 
patients, any angiographic reperfusion improvement was noted 
in 87 (48.1%). The association of angiographic reperfusion im-
provement with mRS ≤2 remained comparable to the complete 
cohort (aOR, 5.15; 95% CI, 1.91 to 13.93).
Discussion
This study has the following main findings. (1) Substantial het-
erogeneity regarding the frequency, dose and indications for IA 
fibrinolytics during or after MT can be observed across different 
centers. (2) In a considerable proportion of patients, IA fibrino-
lytics were administered after 4.5 hours, but the majority 
(>80%) of patients received IA fibrinolytics within 6 hours after 
symptom-onset. (3) Rates of sICH were twice as high compared 
to rates of sICH reported in the Highly Effective Reperfusion Us-
ing Multiple Endovascular Devices (HERMES) collaboration or 
the Efficacy and safety of nerinetide for the treatment of acute 
ischaemic stroke (ESCAPE-NA1) trial (8.8% vs. 3.9%/4.4%),6,22 
particularly after rescue of low TICI scores or treatment of in-
tracranial ICA occlusions. (4) Any angiographic reperfusion im-
provement was observed in half of the patients with around 
one-third resulting in a TICI grade change. (5) Any angiographic 
reperfusion improvement after IA fibrinolytics was associated 
with better outcomes.
Frequency and indications
Depending on the survey, 39% and 60.6% of survey respon-
dents stated using IA thrombolytics in contemporary MT prac-
tice.18,23 In our multi-center analysis, the overall rate of IA fibri-
nolytics administrations was only 5.5% of all anterior circula-
tion large-vessel occlusion MT cases, corroborating the survey’s 
finding that around 50% of interventionalists only treat 1 to 5 
cases/year with IA rtPA.23 However, considerable heterogeneity 
in IA fibrinolytic frequency was noted across centers, with 
some centers utilizing IA tPA in every fourth patient undergo-
ing MT. Median dose of IA tPA was 10 mg, which is within the 
range of previous observational reports15 and dosage regimens 
applied in the THRombectomie des Artères CErebrales (THRA-
CE) trial (mean dose, 8.8 mg).24 In line with the Prolyse in Acute 
Cerebral Thromboembolism II (PROACT-II) inclusion criteria, 
most patients were treated within 6 hours after symptom-on-
set, but a considerable proportion of patients was treated be-
yond 4.5 hours.25 Treatment outside of IV tPA eligibility criteria 
was also evident considering the inclusion of very low ASPECTS 
cases (n=19, ASPECTS <5) and treatment of patients with prior 
anticoagulation (16%).
Risk of bleeding
sICH has always been a major concern in patients treated with 
IA fibrinolytics. Meta-analysis of randomized-controlled trials 
(RCTs) evaluating IA fibrinolytics as stand-alone approach ob-
served a 6.6% excess risk of sICH in patients treated with IA fi-
brinolytics as compared to controls (OR, 2.87; 8.9% vs. 2.3%, 
number needed to harm 15).26 However, no excess in mortality 
was found (20.5% vs. 24.0%).26 In this multi-center single-arm 
observational cohort, we found an overall sICH rate of 8.8% 
(95% CI, 5.9 to 12.5). This compares unfavorable to rates of 
sICH reported in HERMES (4.4%)22 and ESCAPE-NA1 (3.9%).6 
However, there are many constraints associated with a direct 
comparison. First, this observational cohort included patients 
with pre-stroke disability, patients under oral anticoagulation 
and lower ASPECTS as compared to recent RCTs. Second, and 
maybe most importantly, there was a severe selection bias to-
wards poor reperfusion grades and hence, lengthy procedure, 
because an incomplete reperfusion status was the main indica-
tion for administering IA fibrinolytics. Patients in whom no re-
perfusion or only incomplete reperfusion can be achieved have 
significantly higher rates of sICH,27-29 and this association was 
also observed in our data.
Nevertheless, known excess risk from IA fibrinolytics RCTs 
and the possibility of an up to tripled sICH risk in this study 
(considering the upper 95% CI reported here) should prompt 
very careful patient selection. This comprises identification of 
patients with an a priori high risk of sICH, including patients 
with initial TICI0/1 and intracranial ICA occlusion as observed 
in our cohort. Also other, more general factors associated with 
sICH in other MT cohorts like history of diabetes, high blood 
pressure, age, high NIHSS, low ASPECTS, and poor collaterals 
should be acknowledged.27,29 The lack of a statistically signifi-
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cant association of sICH and prior IV tPA, Aspirin or anticoagu-
lant intake should not be mistaken for clear safety signals, as 
the number of patients included in these subgroups were small, 
uncertainty is high and the point estimates were directed to-
wards an increased risk. We did not observe a clear association 
of dose-risk effects, which has been reported by others.30 How-
ever, as dose-regimens were not randomized, we cannot ex-
clude that doses applied were modified according to the pa-
tients presumed risk of bleeding, including pretreatment with 
IV tPA.
Surprisingly, the rate of sICH appeared lower after IA UK as 
compared to IA tPA, which seemed tangible after adjustment 
for clinical confounders and baseline imbalances between the 
groups. There is some preclinical evidence that UK upregulates 
blood brain barrier tight junctions and has a more favorable 
effect on matrix metalloproteinases, potentially lowering the 
risk of bleeding in comparison to tPA.31,32 However, we want to 
stress that this result was not statistically significant and 
should be interpreted cautiously. Patients treated with IA UK 
were treated at one center only, while IA tPA patients were 
treated at nine different European centers. While we have tried 
to account for baseline differences between the groups, there 
is considerable room for hidden bias reflecting the centers in-
dividual decisions and practice to select patients for MT+IA fi-
brinolytic treatments.
Angiographic reperfusion improvement
Any angiographic reperfusion improvement was observed in 
approximately 50% of patients. These results corroborate pre-
vious observations, showing that administration of IA fibrino-
lytics improved reperfusion after failed MT.14 Notably, angio-
graphic control runs were usually performed immediately after 
termination of the IA fibrinolytics infusion. Despite this promis-
ing observation and plausible causality, there is some uncer-
tainty regarding the degree of this observation caused by IA fi-
brinolytics. Theoretically some of the observed residual capillary 
perfusion deficits may also dissolve spontaneously (i.e., without 
additional administration of IA fibrinolytics), if angiographic 
control runs would have been performed with a considerable 
delay in patients without additional administration of IA fibri-
nolytics. 
On the other hand, we were unable to evaluate delayed re-
perfusion after administration of IA fibrinolytics and hence, the 
observed efficacy may seem artificially low. Despite a confine-
ment to the immediate post-infusion period, however, angio-
graphic reperfusion improvement was associated with superior 
functional outcomes and a 12.1% absolute increase of mRS 
≤2, which underlines the notion that even small reperfusion 
improvements may be clinically significant.
Outlook
Almost half of the interventionalists believe that IA thromboly-
sis may have a role in modern endovascular practice, but cur-
rent evidence is still limited.23 Currently, there are two ongoing 
trials evaluating IA fibrinolytics as adjunct to MT. The Boosting 
REcanalization of Thrombectomy for Ischemic Stroke by Intra-
arterial TNK (BRETIS-TNK) pilot study (clinicaltrials.gov, 
NCT04202458) will assess the safety and efficacy of IA te-
necteplase continuously administered after the first attempt of 
a thrombectomy device pass. The CHemical OptImization of 
Cerebral Embolectomy (CHOICE) trial will randomize patients 
with TICI2b reperfusion to receive either a 30-minute IA infu-
sion of weight-adapted tPA or IA placebo.33 The present study 
suggests that although TICI grade improvement occurs only in 
one-third of patients, even small non-TICI grade relevant angi-
ographic perfusion improvements are associated with favorable 
outcomes. Because in our single-arm cohort we could not ex-
clude a potentially up to tripled risk of sICH, future observa-
tional studies should compare patients with MT+IA to patients 
with MT and failed or incomplete reperfusion without addi-
tional rescue IA fibrinolytics. Such studies may also incorporate 
an assessment of delayed reperfusion, which’s rates remain 
unknown from currently available analyses.
Limitations
This is a retrospective single-arm observational study with its 
associated limitations. First, angiographic efficacy analyses 
were performed at each center independently, giving rise to in-
ter-rater variability. Second, generalizability of the findings is 
limited, because the IA+MT cohort constitutes only 5.5% of all 
patients treated for anterior circulation large vessel occlusion 
at the ten participating centers. Hence, there is a very high 
chance of selection bias and rates of sICH may be even higher 
in an unselected cohort. Third, eleven patients (3.5%) were lost 
to follow-up regarding functional outcomes, leading to attri-
tion bias. Finally, comparison of rates of sICH with RCT trial 
data is limited by differences in baseline patient characteristics 
and a selection bias towards poor reperfusion grades.
Conclusions
Administration of IA fibrinolytics as adjunct to MT is performed 
rarely, but can improve reperfusion, which is associated with 
better outcomes. Even when considering a selection bias favor-
ing patients with poor reperfusion, an excess risk of sICH seems 
possible, which should prompt careful patient selection, partic-
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ularly in patients with intracranial ICA occlusions or attempted 
rescue of a TICI0/1 reperfusion. Potential differences regarding 
the rates of sICH between IA UK and IA tPA after MT warrant 
further studies.
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2020.01788.
Disclosure
Johannes Kaesmacher reports grants by the Bangerter-Rhyner-
Foundation and the Swiss Academy of Medical Sciences related 
to the project. Urs Fischer reports grants from Medtronic dur-
ing the conduct of the study, grants and other from Medtronic, 
and other from Medtronic, Stryker, and CSL Behring outside 
the submitted work. Jan Gralla reports grants from Medtronic 
and other from Penumbra outside the submitted work. All oth-
er authors report no conflict of interests.
Acknowledgments
The research was supported by the Bangerter-Rhyner-Founda-
tion and the Swiss Academy of Medical Sciences (Johannes 
Kaesmacher, grant paid to institution). The funder did not take 
part in conceptualization, drafting or approval of the manu-
script. 
References
1. Rizvi A, Seyedsaadat SM, Murad MH, Brinjikji W, Fitzgerald 
ST, Kadirvel R, et al. Redefining 'success': a systematic review 
and meta-analysis comparing outcomes between incomplete 
and complete revascularization. J Neurointerv Surg 2019;11: 
9-13.
2. Liebeskind DS, Bracard S, Guillemin F, Jahan R, Jovin TG, Ma-
joie CB, et al. eTICI reperfusion: defining success in endovas-
cular stroke therapy. J Neurointerv Surg 2019;11:433-438.
3. Kaesmacher J, Dobrocky T, Heldner MR, Bellwald S, Mosi-
mann PJ, Mordasini P, et al. Systematic review and meta-
analysis on outcome differences among patients with TICI2b 
versus TICI3 reperfusions: success revisited. J Neurol Neuro-
surg Psychiatry 2018;89:910-917.
4. Kaesmacher J, Gralla J, Mosimann PJ, Zibold F, Heldner MR, 
Piechowiak E, et al. Reasons for reperfusion failures in stent-
retriever-based thrombectomy: registry analysis and proposal 
of a classification system. AJNR Am J Neuroradiol 2018;39: 
1848-1853.
5. Leischner H, Flottmann F, Hanning U, Broocks G, Faizy TD, 
Deb-Chatterji M, et al. Reasons for failed endovascular re-
canalization attempts in stroke patients. J Neurointerv Surg 
2019;11:439-442.
6. Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, 
Demchuk AM, et al. Efficacy and safety of nerinetide for the 
treatment of acute ischaemic stroke (ESCAPE-NA1): a multi-
centre, double-blind, randomised controlled trial. Lancet 
2020;395:878-887.
7. Baek JH, Kim BM, Kim DJ, Heo JH, Nam HS, Yoo J. Stenting 
as a rescue treatment after failure of mechanical thrombec-
tomy for anterior circulation large artery occlusion. Stroke 
2016;47:2360-2363.
8. Meyer L, Fiehler J, Thomalla G, Krause LU, Lowens S, Ro-
thaupt J, et al. Intracranial stenting after failed thrombecto-
my in patients with moderately severe stroke: a multicenter 
cohort study. Front Neurol 2020;11:97.
9. Chang Y, Kim BM, Bang OY, Baek JH, Heo JH, Nam HS, et al. 
Rescue stenting for failed mechanical thrombectomy in 
acute ischemic stroke: a multicenter experience. Stroke 
2018;49:958-964.
10. Grossberg JA, Rebello LC, Haussen DC, Bouslama M, Bowen 
M, Barreira CM, et al. Beyond large vessel occlusion strokes: 
distal occlusion thrombectomy. Stroke 2018;49:1662-1668.
11. Goyal M, Ospel JM, Menon BK, Hill MD. MeVO: the next 
frontier? J Neurointerv Surg 2020;12:545-547.
12. Kaesmacher J, Maegerlein C, Zibold F, Wunderlich S, Zimmer 
C, Friedrich B. Improving mTICI2b reperfusion to mTICI2c/3 
reperfusions: a retrospective observational study assessing 
technical feasibility, safety and clinical efficacy. Eur Radiol 
2018;28:274-282.
13. Yang M, Huo X, Gao F, Wang A, Ma N, Shi H, et al. Low-dose 
rescue tirofiban in mechanical thrombectomy for acute cere-
bral large-artery occlusion. Eur J Neurol 2020;27:1056-1061.
14. Zaidi SF, Castonguay AC, Jumaa MA, Malisch TW, Linfante I, 
Marden FA, et al. Intraarterial thrombolysis as rescue therapy 
for large vessel occlusions. Stroke 2019;50:1003-1006.
15. Anadani M, Ajinkya S, Alawieh A, Vargas J, Chatterjee A, Turk 
A, et al. Intra-arterial tissue plasminogen activator is a safe 
rescue therapy with mechanical thrombectomy. World Neu-
rosurg 2019;123:e604-e608.
16. Kaesmacher J, Bellwald S, Dobrocky T, Meinel TR, Piechowiak 
EI, Goeldlin M, et al. Safety and efficacy of intra-arterial uro-
kinase after failed, unsuccessful, or incomplete mechanical 
thrombectomy in anterior circulation large-vessel occlusion 
stroke. JAMA Neurol 2020;77:318-326.
17. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bam-
Kaesmacher et al.  Adjunct IA Thrombolysis after Thrombectomy
https://doi.org/10.5853//jos.2020.01788102 http://j-stroke.org
bakidis NC, Becker K, et al. Guidelines for the early manage-
ment of patients with acute ischemic stroke: 2019 update to 
the 2018 guidelines for the early management of acute isch-
emic stroke: a guideline for healthcare professionals from 
the American Heart Association/American Stroke Associa-
tion. Stroke 2019;50:e344-e418.
18. Kellert L, Wollenweber FA, Thomalla G, Nolte CH, Fiehler J, 
Ringleb PA, et al. Thrombolysis management in thrombecto-
my patients: real-life data from German stroke centres. Eur 
Stroke J 2017;2:356-360.
19. Heiferman DM, Li DD, Pecoraro NC, Smolenski AM, Tsimpas 
A, Ashley WW Jr. Intra-arterial alteplase thrombolysis during 
mechanical thrombectomy for acute ischemic stroke. J 
Stroke Cerebrovasc Dis 2017;26:3004-3008.
20. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Mei-
er D, et al. Randomised double-blind placebo-controlled trial 
of thrombolytic therapy with intravenous alteplase in acute 
ischaemic stroke (ECASS II). Second European-Australasian 
Acute Stroke Study Investigators. Lancet 1998;352:1245-
1251.
21. Clopper CJ, Pearson ES. The use of confidence or fiducial lim-
its illustrated in the case of the binomial. Biometrika 1934; 
26:404-413. 
22. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, 
Demchuk AM, et al. Endovascular thrombectomy after large-
vessel ischaemic stroke: a meta-analysis of individual patient 
data from five randomised trials. Lancet 2016;387:1723-
1731.
23. Castonguay AC, Jumaa MA, Zaidat OO, Haussen DC, Jadhav 
A, Salahuddin H, et al. Insights into intra-arterial thromboly-
sis in the modern era of mechanical thrombectomy. Front 
Neurol 2019;10:1195.
24. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, 
Moulin T, et al. Mechanical thrombectomy after intravenous 
alteplase versus alteplase alone after stroke (THRACE): a ran-
domised controlled trial. Lancet Neurol 2016;15:1138-1147.
25. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, 
et al. Intra-arterial prourokinase for acute ischemic stroke. 
The PROACT II study: a randomized controlled trial. Prolyse in 
Acute Cerebral Thromboembolism. JAMA 1999;282:2003-
2011.
26. Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinoly-
sis for acute ischemic stroke: meta-analysis of randomized 
controlled trials. Stroke 2010;41:932-937.
27. Cappellari M, Mangiafico S, Saia V, Pracucci G, Nappini S, 
Nencini P, et al. IER-SICH nomogram to predict symptomatic 
intracerebral hemorrhage after thrombectomy for stroke. 
Stroke 2019;50:909-916.
28. Lee YB, Yoon W, Lee YY, Kim SK, Baek BH, Kim JT, et al. Predic-
tors and impact of hemorrhagic transformations after endo-
vascular thrombectomy in patients with acute large vessel oc-
clusions. J Neurointerv Surg 2019;11:469-473.
29. Kaesmacher J, Kaesmacher M, Maegerlein C, Zimmer C, 
Gersing AS, Wunderlich S, et al. Hemorrhagic transforma-
tions after thrombectomy: risk factors and clinical relevance. 
Cerebrovasc Dis 2017;43:294-304.
30. Hassan AE, Abd-Allah F, Chaudhry SA, Adil MM, Rostambeigi 
N, Qureshi AI. A critical analysis of intra-arterial thrombolyt-
ic doses in acute ischemic stroke treatment. Neurocrit Care 
2014;21:119-123.
31. Kadir RRA, Bayraktutan U. Urokinase plasminogen activator: 
a potential thrombolytic agent for ischaemic stroke. Cell Mol 
Neurobiol 2020;40:347-355.
32. Tan Q, Chen Q, Niu Y, Feng Z, Li L, Tao Y, et al. Urokinase, a 
promising candidate for fibrinolytic therapy for intracerebral 
hemorrhage. J Neurosurg 2017;126:548-557.
33. Renú A, Blasco J, Millán M, Martí-Fàbregas J, Cardona P, 
Oleaga L, et al. The chemical optimization of cerebral embo-
lectomy trial: study protocol. Int J Stroke 2019 Dec 18 [Epub]. 
https://doi.org/10.1177/1747493019895656.
Vol. 23 / No. 1 / January 2021
https://doi.org/10.5853//jos.2020.01788 http://j-stroke.org 1
Supplementary Table 1. Logistic regression model (dependent variable symptomatic intracranial hemorrhage)
Variable aOR 95% CI P
IA UK vs. IA tPA 0.53 0.27–1.04 0.064
Age (per year increase) 1.01 0.97–1.05 0.727
Female sex 0.30 0.095–0.97 0.044*
Admission NIHSS (per point increase) 0.97 0.88–1.06 0.474
Admission ASPECTS (per point increase) 0.78 0.58–1.06 0.110
Symptom-onset/last-seen well to reperfusion (per minute increase) 1.00 0.99–1.00 0.580
TICI (per grade increase) 0.43 0.20–0.94 0.035*
History of diabetes 1.16 0.41–3.24 0.783
History of coronary artery disease 1.25 0.44–3.53 0.672
Anticoagulants
No anticoagulants Baseline Baseline Baseline
Vitamin K antagonists 1.05 0.11–10.13 0.963
Direct oral anticoagulants 3.08 0.55–17.28 0.201
Antiplatelet medication
No antiplatelet medication Baseline Baseline Baseline
Aspirin 2.30 0.74–7.09 0.146
Aspirin+other antithrombotic Did not converge Did not converge Did not converge
Admission imaging modality CT vs. MRI 0.52 0.14–1.92 0.328
IV tPA 2.33 0.75–7.17 0.142
Site of intracranial occlusion
Intracranial ICA Baseline Baseline Baseline
M1 0.27 0.08–0.86 0.026*
M2 0.29 0.07–1.14 0.077
M1/M2, first and second segment of the middle cerebral artery, respectively.
aOR, adjusted odds ratio; CI, confidence interval; IA, intra-arterial; UK, Urokinase; tPA, tissue plasminogen activator; NIHSS, National Institutes of Health Stroke Scale; 
ASPECTS, Alberta Stroke Program Early CT Score; TICI, thrombolysis in cerebral infarction; CT, computed tomography; MRI, magnetic resonance imaging; IV, intravenous; 
ICA, internal carotid artery. 
*P<0.05.
Supplementary Table 2. Risk of symptomatic intracranial hemorrhage with strata of prior antithrombotic and oral anticoagulant intake
No sICH sICH
Antiplatelet medication*
No antiplatelet medication 199 (91.7) 18 (8.3)
Aspirin 70 (88.6) 9 (11.4)
Aspirin+another antiplatelet medication (e.g., prasugrel) 9 (100) 0 (0)
P 0.59
Oral anticoagulants†
No oral anticoagulant medication 126 (91.8) 21 (8.2)
Vitamin K antagonists 22 (91.7) 2 (8.3)
Direct oral anticoagulants 21 (84.0) 4 (16.0)
P 0.44
Values are presented as number (%). P-value calculated using Fisher’s exact test.
sICH, symptomatic intracranial hemorrhage. 
*Data available for 308 patients; †Data available for 309 patients.
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Supplementary Table 3. Any angiographic reperfusion improvement with strata of initial reperfusion success and occlusion site
Strata 
Any angiographic reperfusion improvement
P
— +
TICI before IA fibrinolytics
0 8 (44.4) 10 (55.6) 0.21
1 4 (40.0) 6 (60)
2a 18 (37.5) 30 (62.5)
2b 82 (53.9) 70 (46.1)
Site of occlusion
Intracranial ICA 19 (46.3) 22 (53.7) 0.90
M1 64 (50.4) 63 (49.6)
M2 29 (48.3) 31 (51.7)
Total 112 (49.6) 116 (50.9)
Values are presented as number (%). M1/M2, first/second segment of the middle cerebral artery. P-value were calculated using Fisher’s exact test.
TICI, thrombolysis in cerebral infarction; IA, intra-arterial; ICA, internal carotid artery. 
Supplementary Table 4. Logistic regression model (dependent variable mRS ≤2)
Variable aOR 95% CI P
IA UK vs. IA tPA 1.35 0.87–2.98 0.178
Age (per year increase) 0.94 0.91–0.96 <0.001*
Female sex 0.58 0.28–1.21 0.148
Admission NIHSS (per point increase) 0.88 0.83–0.94 <0.001*
Admission ASPECTS (per point increase) 1.05 0.84–1.31 0.686
Symptom-onset/last-seen well to reperfusion (per minute increase) 0.99 0.99–1.00 0.087
TICI (per grade increase) 2.36 1.26–4.13 0.007*
History of diabetes 0.38 0.16–0.91 0.030†
History of coronary artery disease 0.22 0.10–0.49 <0.001*
Anticoagulants
No anticoagulants Baseline Baseline Baseline
Vitamin K antagonists 0.88 0.22–3.46 0.855
Direct oral anticoagulants 0.09 0.01–0.56 0.009*
Antiplatelet medication
No antiplatelet medication Baseline Baseline Baseline
Aspirin 1.05 0.45–2.43 0.918
Aspirin+other antithrombotic 1.28 0.21–7.67 0.791
Admission imaging modality CT vs. MRI 2.38 0.99–5.68 0.051
IV tPA 1.35 0.63–2.87 0.442
Site of intracranial occlusion
Intracranial ICA Baseline Baseline Baseline
M1 1.99 0.73–5.44 0.175
M2 5.22 1.67–16.27 0.004*
M1/M2, first and second segment of the middle cerebral artery, respectively.
mRS, modified Rankin Scale; aOR, adjusted odds ratio; CI, confidence interval; IA, intra-arterial; UK, urokinase; tPA, tissue plasminogen activator; NIHSS, Na-
tional Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; TICI, thrombolysis in cerberal infarction; IV, intravenous; ICA, internal 
carotid artery.
*P<0.01; †P<0.05.
